Tremfya Prior Authorization for Oncology Patients

The Nuance of Tremfya Prior Authorization in Oncology Patient Populations

Tremfya (guselkumab) is an IL-23 inhibitor indicated for conditions such as moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease. While not an oncology therapeutic, cancer patients frequently present with comorbidities that necessitate such biologics. Prior authorization for Tremfya in an oncology patient requires careful consideration of the patient's cancer diagnosis, current treatment regimen, performance status, and potential drug interactions or contraindications.

Key Documentation for Biologic Prior Authorizations in Complex Patients

• Diagnosis confirmation for the Tremfya indication (e.g., pathology for psoriasis, imaging for psoriatic arthritis).
• Documentation of prior-line treatments for the comorbidity, including response and rationale for escalation to Tremfya.
• Patient's current ECOG or Karnofsky performance status, accounting for cancer treatment effects.
• Detailed list of all concomitant medications, including oncology agents, to assess for potential drug interactions.
• Relevant organ function tests (e.g., hepatic, renal) and infectious disease screening results.

Navigating Medical vs. Pharmacy Benefit for Comorbid Therapies

Oncology drugs are often split between medical and pharmacy benefits, a complexity that extends to non-oncology biologics like Tremfya. Depending on the payer and specific plan, Tremfya may be covered under the medical benefit (for provider-administered injections) or the pharmacy benefit (for self-administered forms). This distinction dictates the PA submission pathway, routing through either the payer's medical PA channel (e.g., X12 278) or the PBM's ePA partners (e.g., NCPDP SCRIPT), requiring robust system integration to manage concurrent PA streams for the same patient.

Common Prior Authorization Denials for Non-Oncology Biologics in Cancer Care

• **Step Therapy Requirements:** Payer requires failure or contraindication to less costly alternatives before approving Tremfya, even if the patient's oncology treatment complicates the use of alternatives.
• **Documentation Gaps:** Missing or incomplete information regarding prior therapies for the comorbidity, or insufficient detail on the impact of cancer treatment on current health status.
• **Off-Label Use:** Request for Tremfya for an indication not approved by FDA or supported by payer policy, or lack of compendium support for specific clinical contexts.
• **Performance Status Concerns:** Payer questions the appropriateness of initiating a new biologic due to a patient's compromised performance status from cancer or its treatment.
• **Concurrent Therapy Conflicts:** Payer flags potential drug interactions or contraindications with ongoing oncology treatments, requiring additional clinical justification.

Klivira's Approach to Streamlining Prior Authorization for Complex Oncology Cases

Klivira’s prior authorization automation platform is designed to manage the high volume and complexity inherent in oncology PA, including situations where patients require non-oncology biologics like Tremfya for comorbidities. Our system's NCCN-compendium-aware logic, regimen-level PA workflows, and intelligent medical-vs-pharmacy benefit routing ensure that all PA events for an oncology patient, regardless of the drug's primary indication, are tracked and processed efficiently. This includes concurrent PA tracking for dozens of events per patient over a treatment course, minimizing delays and supporting continuity of care.